← Browse by Condition
Medical Condition
egfr gene mutation
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2
NCT06643000
Recruiting
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Enrollment
60 pts
Location
China
Sponsor
Henan Cancer Hospital
NCT06716580
Recruiting
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Enrollment
1,000 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT04322890 Phase 2
Recruiting
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Enrollment
6,000 pts
Location
China
Sponsor
Hunan Province Tumor Hospital